Elixiron Immunotherapeutics is a biotechnology company founded in 2017 with a focus on next-generation cancer therapeutics and medicines for unmet needs in immunological and degenerative diseases. Besides EI1071, Elixiron has several other early development candidates including a potential first-in-class therapeutic antibody, EI001, for the treatment of patients with chronic hepatitis B.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.